Oramed Pharmaceuticals Logo
US68403P2039
A1CTNU
ORMP.TA

Oramed Pharmaceuticals

Previsión

Comprar
  6
Mantener
  2
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • Lifeward shareholders approve partnership with Oramed and potential capital injection

    Lifeward has approved the issuance of common shares as part of a strategic partnership with Oramed, potentially giving the company access to up to about $47 million from Oramed and an additional investor. The financing includes equity, convertible bonds, milestone payments and warrants. Oramed will manage and fund the clinical development program for the POD technology, which aims to enable oral delivery of biopharmaceuticals, while Lifeward will focus on its medical technology business. Lifeward shares jumped more than 10% after the announcement but remain down around 65% year-to-date; completion of the transaction is still subject to customary conditions. » Más en de.investing.com


  • Oramed receives $18 million from Scilex and announces cash dividend

    Oramed has received a payment of $18 million from Scilex, fulfilling all obligations under an option agreement and raising the total return on the original $99.5 million investment to $118 million. Oramed also retains a $27 million promissory note, a $12 million convertible note (conversion price $36 per share), warrants and a nine‑year royalty/license interest in Scilex products. The board approved a cash dividend of $0.25 per share (ex‑date January 16, 2026; payment January 26, 2026), to be financed from surplus funds; the share price then rose by about 6.2%. » Más en de.investing.com


  • Oramed Pharmaceuticals: Leonard Sank steps down from director post after 18 years

    Leonard Sank has announced he will resign his mandate on the supervisory board of Oramed Pharmaceuticals effective January 1, 2026. The company emphasizes that his resignation is not due to disagreements over management, policies, or practices. Sank served 18 years as a director. » Más en de.investing.com


  • Oramed completes repurchase of Scilex warrants for $28.5m

    Oramed received a total of $28.5 million from Scilex for the repurchase of warrants to acquire 6,500,000 Scilex common shares (two tranches: 3,370,000 shares for $14 million and 3,130,000 shares for $13 million, plus $1.5 million in option fees). The warrants had an exercise price of $0.01 and were repurchased under an agreement disclosed in July. In addition, Oramed repurchased 1,155,367 of its own common shares for about $2.58 million and ended a joint venture with HTIT/Technowl; the company now plans to continue its oral insulin program independently and to initiate a new U.S. study. » Más en de.investing.com


  • Oramed buys back HTIT shares and ends joint venture

    Oramed repurchased 1,155,367 common shares of Hefei Tianhui Biotech (HTIT) at $2.23 each (about $2.58 million) and had the shares cancelled. The company terminated the joint-venture agreement with HTIT and Technowl after HTIT failed to meet closing conditions. Oramed released preliminary, unaudited financials as of September 30, 2025, and launched a new U.S. study for its oral insulin program with 60 identified high responders. It also completed the first tranche of an option repurchase agreement with Scilex (3,130,000 shares for $13 million) and increased the number of authorized shares under its stock option plan by 2,000,000 to 9,500,000. » Más en de.investing.com

En 2026, Oramed Pharmaceuticals ya ha pagado 0,21 € en dividendos. El último pago fue en enero.

Datos financieros

En el último trimestre, Oramed Pharmaceuticals tuvo unos ingresos de 0 € y un beneficio neto de 16,25 M €

(EUR) septiembre de 2026
YoY
Ingresos 0 -
Beneficio bruto 0 100,00 %
Beneficio neto 16,25 M 60,59 %
EBITDA 24,99 M 50,69 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
141,48 M €
Número de acciones
43,49 M
Máximo/mínimo de 52 semanas
4,99 € - 2,30 €
Rentabilidad por dividendo
6,00 %
Dividendos TTM
0,21 €
Beta
1,28
Ratio P/E
1,02
Ratio PEG
0,00
Ratio P/B
0,44
Ratio P/S
0,00

Perfil de la empresa

Oramed Pharmaceuticals Inc. se dedica a la investigación y el desarrollo de soluciones farmacéuticas para el tratamiento de la diabetes y para el uso de cápsulas o píldoras ingeribles por vía oral para la administración de polipéptidos. Su producto insignia propietario es el ORMD-0801, una cápsula de insulina ingerible por vía oral, que completó los ensayos clínicos de fase II para el tratamiento de personas con diabetes. También desarrolla el ORMD-0901, una cápsula oral de péptido similar al glucagón-1 que ha completado los ensayos clínicos de fase I para el tratamiento de la diabetes tipo 2; y un tratamiento para la pérdida de peso en forma de cápsula oral de leptina. La empresa era conocida anteriormente como Integrated Security Technologies, Inc. y cambió su nombre a Oramed Pharmaceuticals Inc. en abril de 2006. Oramed Pharmaceuticals Inc. fue fundada en 2002 y tiene su sede en Nueva York, Nueva York.

Nombre
Oramed Pharmaceuticals
CEO
Nadav Kidron
Sede New York City, ny
Estados Unidos
Sitio web
Sector
Materiales
Industria
Productos químicos
Salida a bolsa
01/05/2007
Empleados 13

Símbolos bursátiles

Bolsa Símbolo
Tlv
ORMP.TA
NASDAQ
ORMP
Frankfurt
OJU1.F
Düsseldorf
OJU1.DU
München
OJU1.MU
🍪

Parqet  usa cookies. Más información